Express Scripts/Medco Health Solutions
On July 21, 2011, Express Scripts, Inc. (Nasdaq: ESRX) and Medco Health Solutions, Inc. (NYSE: MHS) today announced that they have entered into a definitive merger agreement. Under the agreement, Medco shareholders will receive $71.36 per share in cash and stock, or $29.1 billion.
Medco shareholders will receive $28.80 in cash and 0.81 shares for each Medco share they own upon closing of the transaction.
Detail from the release: "Under the terms of the agreement, Express Scripts shall form a new holding company called Express Scripts Holding Company. Medco shareholders will receive $28.80 in cash and 0.81 shares of Express Scripts Holding Company for each Medco share they own upon closing of the transaction, and Express Scripts shareholders will become shareholders of Express Scripts Holding Company receiving one share of the new holding company for each share of Express Scripts that they own upon closing. Based on the closing price of Express Scripts stock of $52.54 as of July 20, 2011, the stock component is valued at $42.56 per share, which, when combined with the $28.80 in cash brings the total value per share to Medco shareholders of $71.36. This represents a premium to Medco shareholders of 28 percent over Medco's closing share price on July 20, 2011. Upon closing of the transaction, Express Scripts shareholders are expected to own approximately 59 percent of the combined company and Medco shareholders are expected to own approximately 41 percent.
The transaction provides certain value to Medco shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 41 percent of Express Scripts Holding Company shares.
The merger is subject to regulatory clearance and Express Scripts' and Medco's shareholder approvals and other customary closing conditions. The terms of the merger agreement provide for the payment of termination fees in certain circumstances, but not in connection with the failure to obtain regulatory clearance. The transaction is expected to close in the first half of 2012.
The corporate headquarters will be in St. Louis and George Paz will serve as chairman and CEO of the combined organization. The Board of Directors will be expanded to include two current independent Medco board members."
Express Scripts' financial advisors are Credit Suisse and Citigroup Global Markets, Inc. Its legal advisor is Skadden, Arps, Slate, Meagher & Flom, LLP. Medco's co-lead financial advisors are J.P. Morgan and Lazard, its legal advisor is Sullivan & Cromwell LLP and its regulatory counsel is Dechert LLP.
Medco shareholders will receive $28.80 in cash and 0.81 shares for each Medco share they own upon closing of the transaction.
Detail from the release: "Under the terms of the agreement, Express Scripts shall form a new holding company called Express Scripts Holding Company. Medco shareholders will receive $28.80 in cash and 0.81 shares of Express Scripts Holding Company for each Medco share they own upon closing of the transaction, and Express Scripts shareholders will become shareholders of Express Scripts Holding Company receiving one share of the new holding company for each share of Express Scripts that they own upon closing. Based on the closing price of Express Scripts stock of $52.54 as of July 20, 2011, the stock component is valued at $42.56 per share, which, when combined with the $28.80 in cash brings the total value per share to Medco shareholders of $71.36. This represents a premium to Medco shareholders of 28 percent over Medco's closing share price on July 20, 2011. Upon closing of the transaction, Express Scripts shareholders are expected to own approximately 59 percent of the combined company and Medco shareholders are expected to own approximately 41 percent.
The transaction provides certain value to Medco shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 41 percent of Express Scripts Holding Company shares.
The merger is subject to regulatory clearance and Express Scripts' and Medco's shareholder approvals and other customary closing conditions. The terms of the merger agreement provide for the payment of termination fees in certain circumstances, but not in connection with the failure to obtain regulatory clearance. The transaction is expected to close in the first half of 2012.
The corporate headquarters will be in St. Louis and George Paz will serve as chairman and CEO of the combined organization. The Board of Directors will be expanded to include two current independent Medco board members."
Express Scripts' financial advisors are Credit Suisse and Citigroup Global Markets, Inc. Its legal advisor is Skadden, Arps, Slate, Meagher & Flom, LLP. Medco's co-lead financial advisors are J.P. Morgan and Lazard, its legal advisor is Sullivan & Cromwell LLP and its regulatory counsel is Dechert LLP.
View Older Stories
-
Albertsons Companies Names Tom Moriarty Executive Vice President and General Counsel
-
Prime Therapeutics announces Mostafa Kamal as president
-
Walgreens Boots Alliance Strengthens Tech Leadership to Deliver Even Further on the Future of Healthcare
-
Integrated Home Care Services, Inc. Announces Christopher Bradbury as New CEO
-
Michelle Jaeger Appointed President of DAS Health
-
Guardant Health (GH) Appoints Myrtle Potter to Its Board
-
Guardant Health Appoints Myrtle Potter to Its Board of Directors
-
Prime Therapeutics welcomes new client success leader
-
Advanced Dermatology and Cosmetic Surgery Announces the Appointment of Brian T. Griffin as Chief Executive Officer
-
PRA Health Sciences (PRAH) Announces Glen Stettin, M.D. to Board
-
PRA Health Sciences Announces Appointment of New Director
-
PRA Health Sciences Announces Appointment of New Director
-
CB2 Insights Adds Insurance Industry Veteran Pam Galassini to its Leadership Team
-
FSD Pharma Strengthens Management Team
-
Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance
-
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
-
Cigna Corporation Announces Early Results of Exchange Offers and Consent Solicitations for Senior Notes
-
Cigna Corporation Announces Exchange Offers and Consent Solicitations for Senior Notes of Cigna Holding Company, Express Scripts Holding Company and Medco Health Solutions, Inc.
-
Myovant Strengthens Management Team and Adds New Directors to the Board
-
Arbutus Biopharma (ABUS) Appoints James Meyers and Myrtle Potter to Board
-
Arbutus Names New Members to its Board of Directors
-
Arbutus Names New Members to its Board of Directors
-
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
-
Dermavant Announces Changes to Leadership and Board of Directors
-
Roivant Sciences Provides Corporate Updates in Advance of First Annual Pipeline Day
-
Diplomat Pharmacy (DPLO) Appoints Brian Griffin as CEO and Chairman
-
Diplomat Pharmacy Appoints Brian Griffin as Chief Executive Officer and Chairman of the Board
-
Chief Operating Officer Deepti Jain to Lead IngenioRx
-
IBM's Dr. Inderpal Bhandari Named U.S. Chief Data Officer of the Year 2017 by CDO Club
-
Avalon Healthcare Solutions Names Chief Growth Officer and Chief Operating Officer
-
Express Scripts (ESRX) Says Anthem (ANTM) Intends to Move its Business
-
Express Scripts Announces 2017 First Quarter Results; Provides Update on Anthem Relationship and Visibility into Core PBM Business Excluding Contribution from Anthem, Coventry and Catamaran
-
Express Scripts Announces 2016 Fourth Quarter and Full Year Results
-
Fitch Affirms Express Scripts at 'BBB'; Outlook Stable
-
Express Scripts Announces 2016 Third Quarter Results
-
Express Scripts Announces Final Results of Maximum Tender Offers
-
Express Scripts Announces 2016 Second Quarter Results; Narrows 2016 Full-Year Adjusted Diluted EPS Guidance Range; Raises Mid-Point; Provides 2016 Third Quarter Guidance
-
Express Scripts Announces Early Tender Results and Upsizing of Maximum Tender Offers
-
Molecular Health Strengthens U.S. Based Executive Management Team
-
Express Scripts Announces Pricing of Maximum Tender Offers
-
Express Scripts Announces Early Tender Results and Upsizing of Maximum Tender Offers
-
Fitch Rates Express Scripts' Bonds 'BBB'; Outlook Stable
-
Express Scripts Announces Tender Offers for Outstanding Debt Securities
-
Express Scripts Announces 2016 First Quarter Results; Increases 2016 Guidance Range: Raises Mid-Point; Provides 2016 Second Quarter Guidance
-
Fitch Assigns 'BBB' Rating to Express Scripts' (ESRX) New Bonds
-
Fitch Rates Express Scripts Bonds 'BBB'; Outlook Stable
-
Express Scripts Announces 2015 4th Quarter and Full Year Results; Narrows 2016 Guidance Range: Raises Mid-Point
-
Express Scripts (ESRX) Guides FY16 EPS Above Expectations
-
Express Scripts Holding Company Announces 2016 Financial Guidance and Reaffirms 2015 Financial Guidance
-
Fitch Affirms Express Scripts at 'BBB'; Outlook Stable